Cargando…
Therapeutic potential of Bacillus phage lysin PlyB in ocular infections
Bacteriophage lytic enzymes (i.e., phage lysins) are a trending alternative for general antibiotics to combat growing antimicrobial resistance. Gram-positive Bacillus cereus causes one of the most severe forms of intraocular infection, often resulting in complete vision loss. It is an inherently β-l...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449515/ https://www.ncbi.nlm.nih.gov/pubmed/37273201 http://dx.doi.org/10.1128/msphere.00044-23 |
_version_ | 1785094969795543040 |
---|---|
author | Mursalin, Md Huzzatul Astley, Roger Coburn, Phillip S. Bagaruka, Eddy Hunt, Jonathan J. Fischetti, Vincent A. Callegan, Michelle C. |
author_facet | Mursalin, Md Huzzatul Astley, Roger Coburn, Phillip S. Bagaruka, Eddy Hunt, Jonathan J. Fischetti, Vincent A. Callegan, Michelle C. |
author_sort | Mursalin, Md Huzzatul |
collection | PubMed |
description | Bacteriophage lytic enzymes (i.e., phage lysins) are a trending alternative for general antibiotics to combat growing antimicrobial resistance. Gram-positive Bacillus cereus causes one of the most severe forms of intraocular infection, often resulting in complete vision loss. It is an inherently β-lactamase-resistant organism that is highly inflammogenic in the eye, and antibiotics are not often beneficial as the sole therapeutic option for these blinding infections. The use of phage lysins as a treatment for B. cereus ocular infection has never been tested or reported. In this study, the phage lysin PlyB was tested in vitro, demonstrating rapid killing of vegetative B. cereus but not its spores. PlyB was also highly group specific and effectively killed the bacteria in various bacterial growth conditions, including ex vivo rabbit vitreous (Vit). Furthermore, PlyB demonstrated no cytotoxic or hemolytic activity toward human retinal cells or erythrocytes and did not trigger innate activation. In in vivo therapeutic experiments, PlyB was effective in killing B. cereus when administered intravitreally in an experimental endophthalmitis model and topically in an experimental keratitis model. In both models of ocular infection, the effective bactericidal property of PlyB prevented pathological damage to ocular tissues. Thus, PlyB was found to be safe and effective in killing B. cereus in the eye, greatly improving an otherwise devastating outcome. Overall, this study demonstrates that PlyB is a promising therapeutic option for B. cereus eye infections. IMPORTANCE: Eye infections from antibiotic-resistant Bacillus cereus are devastating and can result in blindness with few available treatment options. Bacteriophage lysins are an alternative to conventional antibiotics with the potential to control antibiotic-resistant bacteria. This study demonstrates that a lysin called PlyB can effectively kill B. cereus in two models of B. cereus eye infections, thus treating and preventing the blinding effects of these infections. |
format | Online Article Text |
id | pubmed-10449515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-104495152023-08-25 Therapeutic potential of Bacillus phage lysin PlyB in ocular infections Mursalin, Md Huzzatul Astley, Roger Coburn, Phillip S. Bagaruka, Eddy Hunt, Jonathan J. Fischetti, Vincent A. Callegan, Michelle C. mSphere Research Article Bacteriophage lytic enzymes (i.e., phage lysins) are a trending alternative for general antibiotics to combat growing antimicrobial resistance. Gram-positive Bacillus cereus causes one of the most severe forms of intraocular infection, often resulting in complete vision loss. It is an inherently β-lactamase-resistant organism that is highly inflammogenic in the eye, and antibiotics are not often beneficial as the sole therapeutic option for these blinding infections. The use of phage lysins as a treatment for B. cereus ocular infection has never been tested or reported. In this study, the phage lysin PlyB was tested in vitro, demonstrating rapid killing of vegetative B. cereus but not its spores. PlyB was also highly group specific and effectively killed the bacteria in various bacterial growth conditions, including ex vivo rabbit vitreous (Vit). Furthermore, PlyB demonstrated no cytotoxic or hemolytic activity toward human retinal cells or erythrocytes and did not trigger innate activation. In in vivo therapeutic experiments, PlyB was effective in killing B. cereus when administered intravitreally in an experimental endophthalmitis model and topically in an experimental keratitis model. In both models of ocular infection, the effective bactericidal property of PlyB prevented pathological damage to ocular tissues. Thus, PlyB was found to be safe and effective in killing B. cereus in the eye, greatly improving an otherwise devastating outcome. Overall, this study demonstrates that PlyB is a promising therapeutic option for B. cereus eye infections. IMPORTANCE: Eye infections from antibiotic-resistant Bacillus cereus are devastating and can result in blindness with few available treatment options. Bacteriophage lysins are an alternative to conventional antibiotics with the potential to control antibiotic-resistant bacteria. This study demonstrates that a lysin called PlyB can effectively kill B. cereus in two models of B. cereus eye infections, thus treating and preventing the blinding effects of these infections. American Society for Microbiology 2023-06-05 /pmc/articles/PMC10449515/ /pubmed/37273201 http://dx.doi.org/10.1128/msphere.00044-23 Text en Copyright © 2023 Mursalin et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Mursalin, Md Huzzatul Astley, Roger Coburn, Phillip S. Bagaruka, Eddy Hunt, Jonathan J. Fischetti, Vincent A. Callegan, Michelle C. Therapeutic potential of Bacillus phage lysin PlyB in ocular infections |
title | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections |
title_full | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections |
title_fullStr | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections |
title_full_unstemmed | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections |
title_short | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections |
title_sort | therapeutic potential of bacillus phage lysin plyb in ocular infections |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449515/ https://www.ncbi.nlm.nih.gov/pubmed/37273201 http://dx.doi.org/10.1128/msphere.00044-23 |
work_keys_str_mv | AT mursalinmdhuzzatul therapeuticpotentialofbacillusphagelysinplybinocularinfections AT astleyroger therapeuticpotentialofbacillusphagelysinplybinocularinfections AT coburnphillips therapeuticpotentialofbacillusphagelysinplybinocularinfections AT bagarukaeddy therapeuticpotentialofbacillusphagelysinplybinocularinfections AT huntjonathanj therapeuticpotentialofbacillusphagelysinplybinocularinfections AT fischettivincenta therapeuticpotentialofbacillusphagelysinplybinocularinfections AT calleganmichellec therapeuticpotentialofbacillusphagelysinplybinocularinfections |